Glasgow Prognostic Score (GPS)
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۵۰ • واحد: mg/dL
حداقل ۱ — حداکثر ۶ • واحد: g/dL
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- GPS 00–0
- GPS 11–1
- GPS 22–2
The Glasgow Prognostic Score (GPS) calculates predicting overall survival and disease-free survival across multiple cancer types including colorectal, hepatocellular carcinoma, sarcoma, and lung cancer. Key inputs include crp. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. Routine clinical application promotes standardized evidence-based patient management.
Clinical Guidelines & Evidence
Inflammation and nutrition-based prognostic score for cancer patients using serum C-reactive protein and albumin levels. Predicts overall survival and disease-free survival across multiple cancer types including colorectal, hepatocellular carcinoma, sarcoma, and lung cancer.
Clinical Indication
The Glasgow Prognostic Score (GPS) is indicated for bedside clinical practice to support Inflammation and nutrition-based prognostic score for cancer patients using serum C-reactive protein and albumin levels. Predicts overall survival and disease-free survival across multiple cancer types including colorectal, hepatocellular carcinoma, sarcoma, and lung cancer.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: May guide treatment intensity and palliative care decisions.
Original GPS: Score 0 (CRP ≤1.0 mg/dL AND albumin ≥3.5 g/dL), Score 1 (CRP >1.0 mg/dL OR albumin <3.5 g/dL), Score 2 (CRP >1.0 mg/dL AND albumin <3.5 g/dL). Modified GPS: Score 0 (CRP ≤1.0 mg/dL), Score 1 (CRP >1.0 mg/dL AND albumin ≥3.5 g/dL), Score 2 (CRP >1.0 mg/dL AND albumin <3.5 g/dL)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| crp | float | Yes | C-reactive protein level in mg/dL. Marker of systemic inflammation(mg/dL) |
| albumin | float | Yes | Serum albumin level in g/dL. Marker of nutritional status and liver synthetic function(g/dL) |
| score_type | string | Yes | Type of Glasgow Prognostic Score to calculate |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | GPS 0 | Low risk - Normal inflammation and nutrition |
| 1–1 | GPS 1 | Intermediate risk - Mild inflammation or nutritional compromise |
| 2–2 | GPS 2 | High risk - Severe inflammation and nutritional compromise |
Evidence-Based References (EBM)
- Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89(5):1028-1030.
- McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534-540.
- Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1):149-163.
- Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011;47(17):2633-2641.